Qiagen (QGEN) Receiving Somewhat Favorable Media Coverage, Accern Reports

News coverage about Qiagen (NASDAQ:QGEN) has trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Qiagen earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.6619642100775 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment’s analysis:

Qiagen (QGEN) traded up $0.46 on Friday, hitting $32.65. The stock had a trading volume of 723,291 shares, compared to its average volume of 998,460. The stock has a market capitalization of $7,540.00, a price-to-earnings ratio of 83.72, a P/E/G ratio of 1.80 and a beta of 1.10. Qiagen has a 1-year low of $27.51 and a 1-year high of $36.34. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.78 and a current ratio of 5.33.

Qiagen (NASDAQ:QGEN) last released its earnings results on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.32. The firm had revenue of $364.00 million during the quarter, compared to analyst estimates of $363.42 million. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. Qiagen’s revenue was up 7.5% compared to the same quarter last year. During the same period last year, the business posted $0.29 earnings per share. research analysts expect that Qiagen will post 1.25 earnings per share for the current year.

Several research firms recently commented on QGEN. Zacks Investment Research raised Qiagen from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a report on Tuesday, October 10th. Cowen reissued a “hold” rating and set a $33.00 target price on shares of Qiagen in a research note on Friday, November 3rd. Commerzbank reissued a “buy” rating on shares of Qiagen in a research note on Tuesday, November 7th. BidaskClub raised Qiagen from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. Finally, DZ Bank reissued a “neutral” rating on shares of Qiagen in a research note on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $34.63.

TRADEMARK VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/13/qiagen-qgen-receives-daily-media-impact-score-of-0-16.html.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Insider Buying and Selling by Quarter for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply